TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Free Report) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 1,800,000 shares, an increase of 31.4% from the August 31st total of 1,370,000 shares. Approximately 4.3% of the company’s shares are sold short. Based on an average trading volume of 360,200 shares, the days-to-cover ratio is currently 5.0 days.
TScan Therapeutics Stock Up 1.4 %
Shares of NASDAQ TCRX traded up $0.07 during midday trading on Friday, hitting $5.04. 170,490 shares of the stock traded hands, compared to its average volume of 248,888. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.77 and a current ratio of 7.77. TScan Therapeutics has a one year low of $2.43 and a one year high of $9.69. The business has a 50 day moving average price of $5.97 and a two-hundred day moving average price of $7.01. The company has a market cap of $266.97 million, a PE ratio of -3.88 and a beta of 0.79.
TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. TScan Therapeutics had a negative net margin of 855.84% and a negative return on equity of 59.83%. The business had revenue of $0.54 million during the quarter, compared to analyst estimates of $1.55 million. On average, equities analysts predict that TScan Therapeutics will post -1.36 EPS for the current year.
Analyst Upgrades and Downgrades
View Our Latest Research Report on TCRX
Insider Buying and Selling at TScan Therapeutics
In related news, Director Barbara Klencke bought 5,000 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were purchased at an average cost of $5.69 per share, with a total value of $28,450.00. Following the acquisition, the director now owns 35,000 shares of the company’s stock, valued at $199,150. The purchase was disclosed in a filing with the SEC, which is available through this link. In other news, Director Barbara Klencke bought 5,000 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was acquired at an average price of $5.69 per share, with a total value of $28,450.00. Following the transaction, the director now owns 35,000 shares of the company’s stock, valued at approximately $199,150. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, insider Zoran Zdraveski sold 164,686 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $5.78, for a total transaction of $951,885.08. Following the completion of the transaction, the insider now owns 4,716 shares in the company, valued at approximately $27,258.48. The disclosure for this sale can be found here. In the last ninety days, insiders acquired 15,000 shares of company stock worth $82,550. 2.76% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On TScan Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in TCRX. Vanguard Group Inc. increased its holdings in TScan Therapeutics by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company’s stock worth $14,357,000 after purchasing an additional 20,000 shares in the last quarter. Great Point Partners LLC purchased a new position in shares of TScan Therapeutics during the second quarter valued at approximately $5,504,000. Marshall Wace LLP grew its holdings in TScan Therapeutics by 60.8% during the second quarter. Marshall Wace LLP now owns 307,487 shares of the company’s stock worth $1,799,000 after buying an additional 116,316 shares in the last quarter. Tocqueville Asset Management L.P. purchased a new stake in TScan Therapeutics in the 1st quarter valued at $1,685,000. Finally, Bank of Montreal Can purchased a new stake in TScan Therapeutics in the 2nd quarter valued at $749,000. Institutional investors and hedge funds own 82.83% of the company’s stock.
About TScan Therapeutics
TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
Read More
- Five stocks we like better than TScan Therapeutics
- What is a Special Dividend?
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Options Trading – Understanding Strike Price
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- Transportation Stocks Investing
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.